UBS Group Forecasts Strong Price Appreciation for Perspective Therapeutics (NYSEAMERICAN:CATX) Stock

Key Points

• UBS raised its price target on Perspective Therapeutics from $7 to $8 and kept a buy rating, implying about a 61.6% upside versus the current price; analyst consensus target sits at $12.25 with individual targets up to $16.
• Fundamentals remain weak: the company reported a ($0.51) EPS and just $0.04M in quarterly revenue with very negative margins and ROE, underscoring significant cash burn and reliance on financing or milestone events.
• Clinical progress provides positive momentum—updated [212Pb]VMT‑α‑NET data was accepted for an AACR poster showing no dose‑limiting toxicities, no serious renal issues, and encouraging anti‑tumor activity (76% without progression in an analyzed cohort).

Perspective Therapeutics (NYSEAMERICAN:CATX - Get Free Report) had its price target hoisted by stock analysts at UBS Group from $7.00 to $8.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. UBS Group's target price suggests a potential upside of 61.62% from the company's current price.

CATX has been the subject of a number of other reports. BTIG Research restated a "buy" rating and set a $14.00 target price on shares of Perspective Therapeutics in a report on Tuesday. Wedbush reiterated an "outperform" rating and issued a $11.00 price target on shares of Perspective Therapeutics in a research note on Wednesday. Royal Bank Of Canada cut their price objective on shares of Perspective Therapeutics from $18.00 to $14.00 and set an "outperform" rating on the stock in a report on Tuesday. B. Riley Financial dropped their target price on shares of Perspective Therapeutics from $12.00 to $11.00 and set a "buy" rating on the stock in a research report on Tuesday, November 18th. Finally, Piper Sandler began coverage on Perspective Therapeutics in a report on Thursday, February 19th. They issued an "overweight" rating and a $16.00 price target for the company. One analyst has rated the stock with a Strong Buy rating and eight have given a Buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $12.25.

Perspective Therapeutics Trading Down 5.2%

Shares of Perspective Therapeutics stock opened at $4.95 on Wednesday. The firm's 50-day moving average is $4.26 and its 200 day moving average is $3.42. Perspective Therapeutics has a 1 year low of $1.60 and a 1 year high of $6.16. The company has a current ratio of 8.66, a quick ratio of 8.66 and a debt-to-equity ratio of 0.01.

Perspective Therapeutics (NYSEAMERICAN:CATX - Get Free Report) last released its quarterly earnings data on Monday, March 16th. The company reported ($0.51) EPS for the quarter. The business had revenue of $0.04 million for the quarter. Perspective Therapeutics had a negative net margin of 9,841.86% and a negative return on equity of 40.03%. As a group, equities analysts anticipate that Perspective Therapeutics will post -0.88 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Perspective Therapeutics

Hedge funds have recently modified their holdings of the stock. AXQ Capital LP increased its holdings in Perspective Therapeutics by 24.2% during the 4th quarter. AXQ Capital LP now owns 12,749 shares of the company's stock valued at $35,000 after acquiring an additional 2,481 shares in the last quarter. Deutsche Bank AG raised its holdings in Perspective Therapeutics by 6.1% in the 4th quarter. Deutsche Bank AG now owns 54,245 shares of the company's stock valued at $149,000 after acquiring an additional 3,119 shares during the last quarter. Vontobel Holding Ltd. boosted its holdings in shares of Perspective Therapeutics by 25.0% during the fourth quarter. Vontobel Holding Ltd. now owns 25,000 shares of the company's stock worth $69,000 after purchasing an additional 5,000 shares during the last quarter. Russell Investments Group Ltd. grew its position in shares of Perspective Therapeutics by 184.1% in the third quarter. Russell Investments Group Ltd. now owns 8,449 shares of the company's stock valued at $29,000 after purchasing an additional 5,475 shares during the period. Finally, Taylor & Morgan Wealth Management LLC increased its stake in Perspective Therapeutics by 6.6% in the fourth quarter. Taylor & Morgan Wealth Management LLC now owns 97,000 shares of the company's stock valued at $267,000 after purchasing an additional 6,000 shares during the last quarter. 54.66% of the stock is owned by institutional investors and hedge funds.

More Perspective Therapeutics News

Here are the key news stories impacting Perspective Therapeutics this week:

• Positive Sentiment: Updated [212Pb]VMT-α-NET data accepted for a poster at the AACR Annual Meeting (presentation scheduled April 20). Prior interim data showed no dose‑limiting toxicities, no serious renal issues, and encouraging anti‑tumor activity (76% without progression in an analyzed cohort), which supports the program’s clinical momentum and visibility in oncology. AACR Data Acceptance
• Positive Sentiment: BTIG Research reaffirmed a “Buy” rating and set a $14 price target, signaling continued analyst conviction and providing upside vs. current levels. BTIG Reaffirmation
• Neutral Sentiment: Perspective issued a full-year 2025 results and business highlights update describing progress across its neuroendocrine, melanoma and solid tumor programs and growth of regional finishing facilities; useful for monitoring program cadence but not a near-term revenue driver. Full Year 2025 Results
• Neutral Sentiment: The company is scheduled to release its quarterly earnings on Wednesday — an event that could trigger near-term volatility as investors parse operational and cash‑flow details. Earnings Release Notice
• Negative Sentiment: Latest quarter: reported a ($0.51) EPS and only $0.04M in revenue, with very negative margins and ROE — highlighting ongoing cash burn and dependence on financing or milestones to fund development. This is the principal near‑term negative catalyst pressuring the stock. Quarterly Results
• Negative Sentiment: RBC cut its price target from $18 to $14 (still an Outperform) — a downward revision that tempers upside expectations despite the maintained positive rating. RBC Target Cut

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.